What Leadership Looks Like: The Future of ESG in Healthcare and Biotech

The healthcare ESG story of the next decade will not be written by the companies that produce the most compelling sustainability reports. It will be written by those that have embedded environmental accountability into R&D workflows, built access planning into drug development strategy before Phase 3, structured boards with the expertise to govern at the intersection of clinical science and social obligation, and built supply chains that can withstand the compounding pressures of geopolitical disruption, regulatory scrutiny, and climate-driven physical risk. The distinction between those two categories of company — the performative and the structural — is becoming measurable. And the measurability is what changes the stakes.

Where the Regulatory Arc Is Bending

The EU’s sustainability Omnibus package, which is expected to reduce the number of companies in CSRD scope, has been widely characterised as a retreat. Freshfields’ 2026 ESG trends analysis pushes back on that framing. Even with reduced direct scope, the Omnibus changes do not remove the disclosure requirements for the world’s largest pharmaceutical multinationals. The ISSB standards — which now function as the global baseline for climate and sustainability reporting — still require detailed disclosure of plans and targets for companies with significant capital market exposure. The UK government’s formal consultation on climate transition planning obligations, expected to produce regulation in 2026, is tightening rather than loosening. Australia, Canada, Japan, and South Korea are aligning with or exceeding EU-level requirements.

Datamaran’s analysis, reported in Trellis in March 2026, documented more than 2,000 new environmental regulations introduced globally in 2025 — a figure that itself reflects the paradox of deregulatory political environments: simplification creates new regulation. For healthcare companies, the practical implication is that the aggregate regulatory burden on sustainability reporting is not declining. The jurisdiction of application is changing. The work of meeting it is not.

At the state level in the US, New York implemented mandatory emissions reporting in December 2025 requiring disclosure of 2026 emissions by June 2027. California, Colorado, Oregon, and Washington already have related rules. As these state requirements compound, pharmaceutical manufacturers and healthcare systems with multi-state US operations face a domestic patchwork that is growing more complex, not simpler, regardless of federal deregulatory moves.

The Combination Imperative: Climate, Health, and Medicine

The most intellectually compelling ESG development in healthcare is also the least discussed: the feedback loop between climate change and the diseases that pharmaceutical companies treat. The Lancet Countdown on Health and Climate Change has documented accelerating connections between rising temperatures and the burden of infectious disease, cardiovascular illness, respiratory conditions, and mental health. Dengue fever, vector-borne diseases, and heat-related illness are expanding into geographies where they were previously absent. The populations with the highest burden of climate-related disease are, with significant overlap, those with the least access to pharmaceutical innovation.

This means that healthcare companies’ ESG decisions are not merely about managing their own emissions — they are about managing the environmental conditions that will shape the burden of disease they are treating decades from now. A pharmaceutical company that reduces its carbon footprint while maintaining an access strategy concentrated in wealthy markets is solving half of a two-part problem. The companies building strategy for the next generation are those that see climate adaptation and health equity as complementary challenges with complementary solutions, not as separate reporting categories.

AI Governance: The Emerging ESG Frontier

Artificial intelligence is being deployed across pharmaceutical R&D, clinical trial design, drug pricing, and diagnostics at accelerating pace. Its ESG implications are substantial and underappreciated. Pharmaphorum’s 2026 clinical trial analysis noted that implementation milestones under the EU AI Act and related liability reforms, including the updated Product Liability Directive due by December 2026, will push sponsors and vendors to formalise risk management, documentation, and transparency for high-risk AI systems used in healthcare and life sciences. The legal framework for AI in clinical settings is moving faster than many healthcare companies’ internal governance structures.

The equity dimension of AI in healthcare is acute. Machine learning algorithms trained on historically biased clinical data replicate and can amplify the underrepresentation problems that clinical trial diversity programmes are trying to correct. An AI recruitment tool that identifies high-compliance patients based on prior trial participation data will disproportionately identify patients from the same demographic groups that have historically dominated trial enrollment. Governance of AI in this context is not merely a technology oversight function — it is a social equity function, and it belongs under the ‘S’ of ESG.

Companies that are building ESG-aligned AI governance — auditing training data for demographic representation, publishing algorithmic transparency reports, integrating equity metrics into AI performance assessment — are developing infrastructure that will differentiate them both regulatorily and reputationally as AI oversight frameworks tighten globally. This is currently a leading-edge practice. The regulatory trajectory suggests it will become standard within three to five years.

What Genuine Leadership Looks Like

The companies setting genuine ESG leadership standards in healthcare share a set of operational characteristics that extend well beyond strong sustainability reports:

• They calculate emissions at the level of individual trials, products, and manufacturing batches — not just at the corporate aggregate level. This specificity enables targeted interventions and creates credible accountability.
• They integrate access planning into R&D decisions before Phase 3, not after approval. Pricing strategy, voluntary licensing intent, and LMIC trial placement decisions made before commercial pressure arrives produce structurally different outcomes than those negotiated under post-approval scrutiny.
• They tie meaningful portions of senior executive compensation to sustainability outcomes — not proxy metrics, but operational results: tonnes of CO₂ reduced, access programme patient-reach figures, supplier audit pass rates.
• They disclose supply chain data at tier-two and below, including the manufacturing sub-suppliers whose environmental and labour practices are invisible in tier-one disclosure.
• They build boards with ESG expertise as a defined board-level competency, rather than delegating sustainability oversight entirely to management.

The Freshfields analysis noted that the deregulatory moves by some jurisdictions may paradoxically accelerate ESG-related litigation, as NGOs and civil litigants step into spaces vacated by regulatory enforcement. For healthcare companies, this means that the legal risk of weak ESG performance may be increasing even as the regulatory mandate for disclosure shifts. The combination of investor expectations, mandatory EU reporting, expanding state-level rules, and litigation risk creates a multi-vector accountability environment in which well-intentioned underperformance carries consequences.

The Decade Ahead

Author

Bernice Lottering